Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.
It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 26 | 0.00 Increased by +100.00% | -0.05 Increased by +100.00% |
| Nov 26, 25 | -0.07 Increased by +75.00% | -0.10 Increased by +30.00% |
| Aug 28, 25 | -0.04 Decreased by N/A% | -0.40 Increased by +90.00% |
| May 30, 25 | 0.00 Decreased by N/A% | -0.14 Increased by +100.00% |
| Feb 26, 25 | -0.04 Increased by +69.63% | -0.41 Increased by +90.24% |
| Oct 30, 24 | -0.28 Increased by +3.45% | -0.31 Increased by +9.68% |
| Apr 30, 24 | 0.00 Increased by +100.00% | -0.11 Increased by +100.00% |
| Feb 28, 24 | 0.00 Increased by +100.00% | -0.40 Increased by +100.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 7.02 M Increased by +458.55% | -27.10 M Increased by +2.18% | Decreased by -386.04% Increased by +82.49% |
| Mar 31, 25 | 7.02 M Increased by +458.55% | -27.10 M Increased by +2.18% | Decreased by -386.04% Increased by +82.49% |
| Dec 31, 24 | 1.58 M Decreased by -6.85% | -23.97 M Decreased by -47.31% | Decreased by -1.52 K% Decreased by -58.14% |
| Sep 30, 24 | 1.58 M Decreased by -6.85% | -23.97 M Decreased by -47.31% | Decreased by -1.52 K% Decreased by -58.14% |
| Jun 30, 24 | 1.26 M Decreased by -41.23% | -27.71 M Decreased by -26.41% | Decreased by -2.20 K% Decreased by -115.11% |
| Mar 31, 24 | 1.26 M Decreased by -35.17% | -27.71 M Decreased by -48.97% | Decreased by -2.20 K% Decreased by -129.80% |
| Dec 31, 23 | 1.69 M Decreased by -14.44% | -16.27 M Increased by +33.56% | Decreased by -960.42% Increased by +22.34% |
| Sep 30, 23 | 1.69 M Increased by +17.39% | -16.27 M Increased by +3.64% | Decreased by -960.42% Increased by +17.92% |